

1 Sex-based differences in clearance of chronic *Plasmodium*
2 *falciparum* infection
3

4 Jessica Briggs, M.D.^{1*}, Noam Teyssier, B.S.¹, Joaniter I. Nankabirwa, Ph.D.^{2,3}, John Rek, MSc²,
5 Prasanna Jagannathan, M.D.⁴, Emmanuel Arinatiwe, MPH^{2,9}, Teun Bousema, Ph.D.^{5,6}, Chris
6 Drakeley, Ph.D.⁶, Margaret Murray, M.S.⁴, Emily Crawford, Ph.D.⁷, Nicholas Hathaway, M.D.⁸,
7 Sarah G. Staedke, Ph.D.⁹, David Smith, Ph.D.¹⁰, Phillip J. Rosenthal, M.D.¹, Moses Kamya,
8 Ph.D.^{2,3}, Grant Dorsey, M.D.¹, Isabel Rodriguez-Barraquer, M.D.^{1**},
9 Bryan Greenhouse, M.D.^{1**}

10 **co-senior authors

11

12 ¹ Department of Medicine, University of California San Francisco, San Francisco, CA

13 ²Infectious Diseases Research Collaboration, Kampala, Uganda

14 ³Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda

15 ⁴ Department of Medicine, Stanford University, Palo Alto, CA

16 ⁵ Department of Medical Microbiology, Radboud University Nijmegen Medical Centre,
17 Nijmegen, the Netherlands

18 ⁶ Department of Immunology and Infection, London School of Hygiene and Tropical Medicine,
19 London, UK

20 ⁷Chan-Zuckerberg Biohub, San Francisco, CA

21 ⁸Department of Medicine, University of Massachusetts, Amherst, MA

22 ⁹Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK

23 ¹⁰Institute for Health Metrics & Evaluation, University of Washington, Seattle, WA

24

25

26

27

28 *Corresponding Author: Jessica Briggs, Rm 525 Building 3, Zuckerberg San Francisco
29 General Hospital, San Francisco, CA. Email: jessica.briggs@ucsf.edu

30

31

32

33

34

35

36

37

38 Key words: malaria, asymptomatic infection, force of infection, duration of infection,
39 genotyping, sex-based differences

40 Abstract

41
42 Multiple studies have reported a male bias in incidence and/or prevalence of malaria infection in
43 males compared to females. To test the hypothesis that sex-based differences in host-parasite
44 interactions affect the epidemiology of malaria, we intensively followed *Plasmodium falciparum*
45 infections in a cohort in a malaria endemic area of eastern Uganda and estimated both force of
46 infection (FOI) and rate of clearance using amplicon deep-sequencing. We found no evidence of
47 differences in behavioral risk factors, incidence of malaria, or FOI by sex. In contrast, females
48 cleared asymptomatic infections at a faster rate than males (hazard ratio [HR] = 1.82, 95% CI
49 1.20 to 2.75 by clone and HR = 2.07, 95% CI 1.24 to 3.47 by infection event) in multivariate
50 models adjusted for age, timing of infection onset, and parasite density. These findings implicate
51 biological sex-based differences as an important factor in the host response to this globally
52 important pathogen.

53

54

55

56

57

58

59

60

61 Introduction

62 Malaria, a protozoan infection of the red blood cells, remains one of the greatest global
63 health challenges¹. Infection with malaria parasites results in a wide range of clinical disease
64 presentations, from severe to uncomplicated; in addition, in hyperendemic areas, asymptomatic
65 infections are common². It is well established that chronic asymptomatic infection with
66 *Plasmodium falciparum*, the most common and fatal malaria parasite, can lead to morbidity for
67 those infected and contribute to ongoing transmission^{2–5}. Characterization of these
68 asymptomatic infections is paramount as they represent a major obstacle for malaria elimination
69 efforts. Therefore, an understanding of how host immunity and parasite factors interact to cause
70 disease tolerance is required. While age-specific immunity to malaria in hyperendemic areas is
71 well-characterized, less attention has been paid to the possibility of a sex bias in malarial
72 susceptibility despite evidence for a male bias in malaria infections in non-human animals and a
73 male bias in the prevalence of other human parasitic infections^{6–8}.

74 The clearest evidence for sexual dimorphism in malaria susceptibility is in pregnant
75 women, who are at greater risk of malaria infection and also experience more severe disease
76 and higher mortality⁹. However, multiple studies performed in different contexts have
77 demonstrated a male bias in incidence and/or prevalence of malaria infection in school aged
78 children and adults;^{10–14} this bias is more well established in hypoendemic areas, but has also
79 been observed in hyperendemic regions.^{15,16} It has often been postulated that these differences
80 in malaria incidence or prevalence stem from an increased risk of males acquiring infection due
81 to socio-behavioral factors^{11,13,17,18}. However, biological sex itself has been demonstrated to
82 affect responses to other pathogens, and thus an alternative hypothesis is that the sexes have
83 different responses to the malaria parasite once infected^{19–22}.

85 Estimating the host response to *P. falciparum* infection requires close follow up of
86 infected individuals, sensitive detection of parasites, and the ability to distinguish superinfection,
87 which is common in endemic areas, from persistent infection. To test the hypothesis that sex-
88 based differences in host-parasite interactions affect the epidemiology of malaria, we intensively
89 followed a representative cohort of individuals living in a malaria endemic area of eastern
90 Uganda. Using frequent sampling, ultrasensitive quantitative PCR (qPCR), and amplicon deep
91 sequencing to genotype parasite clones, we were able to accurately detect the onset of new
92 infections and follow all infections over time to estimate their duration. Using these data, we
93 show that females cleared their asymptomatic infections more rapidly than males, implicating
94 biological sex-based differences as important in the host response to this globally important
95 pathogen.

96 **Results**

97

98 **Cohort participants and *P. falciparum* infections**

99 This analysis involved data from 477 children and adults (233 males and 244 females)
100 that were followed for a total of 669.6 person-years (Table 1). 25 participants, 10 males and 15
101 females, were enrolled after initial enrollment (Figure 1); median duration of follow up in those
102 who were dynamically enrolled was 0.84 years (IQR 0.69-1.23) compared to 1.45 years (IQR
103 1.43-1.47) in those enrolled during initial enrollment. 149 of 477 participants (31.2%) included in
104 the analysis had at least one *P. falciparum* infection detected (Figure 1). 114 participants had
105 822 successfully genotyped samples and had infections characterized by clone and by infection
106 event. We achieved a read count of >10,000 for 92% of genotyped samples, identifying 45
107 unique AMA-1 clones in our population (frequencies and sequences in **Supplemental File 1e**).
108 35 samples had very low-density infections (< 1 parasite/ μ L) that could not be genotyped and
109 had infections characterized at the event level only. There were more baseline infections in

110 males at the clone level, with 117/185 (63.2%) baseline infections in males and 68/185 (36.8%)
111 baseline infections in females ($p < 0.001$). At the infection event level, there was no difference in
112 the number of baseline infections by sex, with 54/99 (54.4%) baseline infections in males and
113 45/99 (45.5%) baseline infections in females and ($p = 0.26$).

114

115 **Behavioral malaria risk factors and measures of malaria burden**

116 There was no difference in reported rates of LLIN use the previous night by sex (Table
117 1). Women over the age of 16 traveled overnight outside of the study area more than men
118 (incidence rate ratio [IRR] for females vs. males = 3.61, 95% confidence interval [CI] 1.83 to
119 7.13), a potential risk factor for malaria exposure. Antimalarial use outside the study clinic was
120 reported only 4 times (3 females and 1 male, all under the age of 5). In this region receiving
121 regular rounds of IRS, the incidence of symptomatic malaria was low in all age categories, and
122 there was no evidence of a difference in incidence of symptomatic malaria by sex overall (IRR
123 for females vs. males = 1.11, 95% CI 0.49 to 2.52) or when adjusted for age (IRR = 1.26, 95%
124 CI 0.54 to 2.96). In contrast, prevalence ratio (PR) of *P. falciparum* parasitemia by microscopy in
125 females versus males across all age categories was 0.49 (95% CI 0.36 to 0.65), with relative
126 differences in prevalence most pronounced in the oldest age group. Similar findings were seen
127 when prevalence was assessed by ultrasensitive qPCR, with PR = 0.64 in females vs. males
128 (95% CI 0.43 to 0.96), again with the largest differences seen in the oldest age group. Adjusting
129 for age as a categorical variable, LLIN use, and travel did not qualitatively change prevalence
130 ratios for microscopic parasitemia (PR in females vs. males = 0.57, 95% CI 0.42 to 0.77) or for
131 qPCR-positive parasitemia (PR in females vs. males = 0.67, 95% CI 0.60 to 0.76). We also
132 found no evidence for a difference in parasite density as determined by qPCR between males
133 and females after adjusting for age as a continuous variable ($p = 0.47$). Median COI was higher
134 in males than in females overall, driven primarily by a higher COI in male school aged children.

135

136 **Force of infection by age and sex**

137 To determine whether higher infection prevalence in males was due to an increased rate
138 of infection, we used longitudinal genotyping to calculate the force of infection (FOI, number of
139 new blood stage infections per unit time). Overall, the FOI was low, with new infections
140 occurring on average less than once every 5 years (Table 2). There was no evidence for a
141 significant difference in FOI by sex overall (IRR for females vs. males = 0.88, 95% CI 0.48 to
142 1.62 by clone and IRR = 0.83, 95% CI 0.52 to 1.33 by infection event). There was also no
143 evidence for a significant difference in FOI by sex when adjusted for age category (IRR = 0.88,
144 95% CI 0.47 to 1.63 by clone and IRR = 0.83, 95% CI 0.53 to 1.31 by infection event). For
145 analysis both by clone and by infection event, there was a trend toward higher FOI in males
146 compared to females. We performed a sensitivity analysis by decreasing the number of skips
147 necessary to declare an infection cleared (Supplemental File 1f). Performing the same analysis
148 using 1 skip for clearance instead of 3 skips increased the FOI in all groups and increased the
149 trend toward higher FOI in males, with IRR for females vs. males when adjusted for age
150 category = 0.71, 95% CI 0.41 to 1.24 by clone and IRR = 0.75, 95% CI 0.47 to 1.22 by infection
151 event.

152

153 **Rate of clearance of infection and duration of infection by sex**

154 Since females had a lower prevalence of infection but similar rate of acquiring infections
155 compared to males, we evaluated whether there was a difference between sexes in the rate at
156 which infections were cleared. Asymptomatic infections were included in this analysis if they
157 were not censored as stated in the methods; at the clone level, 105 baseline infections and 53
158 new infections were included. At the infection event level, 58 baseline infections and 51 new
159 infections were included. There were more baseline infections in males at the clone level, with
160 68/105 (64.8%) baseline infections in males and 37/105 (35.2%) baseline infections in females
161 ($p < 0.001$). At the infection event level, there was no difference in the number of baseline

162 infections by sex, with 32/58 (55.2%) baseline infections in males and 26/58 (44.8%) baseline
163 infections in females ($p = 0.35$).

164 Unadjusted hazard ratios for clearing infecting clones showed that asymptomatic
165 infections cleared naturally (*i.e.*, when not treated by antimalarials) at nearly twice the rate in
166 females vs. males (hazard ratio (HR) 1.92, 95% CI 1.19 to 3.11, Table 3). In addition, new
167 infections cleared faster than baseline infections and monoclonal infections cleared faster than
168 polyclonal infections. Unadjusted hazard ratios for clearance of infection events (as opposed to
169 clones) also showed faster clearance in females vs. males (HR = 2.30, 95% CI 1.20 to 4.42).
170 Results were similar in multivariate models including age, gender, the period during which the
171 infection was first observed, and parasite density, demonstrating faster clearance in females vs.
172 males (HR = 1.82, 95% CI 1.20 to 2.75 by clone and HR = 2.07, 95% CI 1.24 to 3.47 by infection
173 event). Complexity of infection was not included in the final adjusted model because the model
174 fit the data less well when COI was included as a predictor. In both adjusted models, new
175 infections cleared faster than baseline infections. Higher parasite densities were associated with
176 slower clearance by clone and by infection event, but the effect size was larger when data were
177 analyzed by infection event (HR = 0.44, 95% CI 0.35 to 0.54). There was no evidence for
178 interaction between age and sex in either adjusted model. We performed a sensitivity analysis
179 by decreasing the number of skips necessary to declare an infection cleared. Regardless of
180 whether 3 skips, 2 skips, or 1 skip was used to determine infection clearance, females cleared
181 their infections faster than males both by clone and by infection event (Supplemental File 1g).

182 We next estimated durations of asymptomatic infection by age and sex using results
183 from a model that included these covariates (Figure 2). Durations of infection ranged from 103
184 days to 447 days by clone, and from 87 to 536 days by infection event. Males had a longer
185 duration of infection across all age categories. Children aged 5-15 years had the longest
186 duration of infection, followed by adults. Therefore, overall, males aged 5-15 years had the
187 longest estimated duration of infection by either clone (447 days) or infection event (526 days).

188

189 **Discussion**

190 Previous studies have reported a higher prevalence of malaria infection in males
191 compared to females, with the difference often ascribed to differences in exposure^{10–16}. In a
192 cohort study in eastern Uganda, we noted higher prevalence of malaria infection in males
193 compared to females. By closely following a cohort of children and adults and genotyping every
194 detected infection with sensitive amplicon deep-sequencing, we were able to estimate both the
195 rate of infection (FOI) and duration of infection and to compare these measures by sex. We
196 found that lower prevalence in females did not appear to be due to lower rates of infection but
197 rather due to faster clearance of asymptomatic infections. To our knowledge, this is the first
198 study to report a sex-based difference in the duration of malaria infection.

199 Many prior studies of malaria incidence and/or prevalence that evaluated associations
200 with sex in late childhood, adolescence and adulthood have found a male bias in the observed
201 measure of burden^{10–16}. Overall, these studies consistently suggest that males exhibit higher
202 incidence and/or prevalence of malaria that begins during late childhood, persisting through
203 puberty and the majority of adulthood (excepting the years when pregnancy puts women at
204 higher risk). One possible explanation put forward for the sex-specific difference in burden has
205 been that males are more frequently bitten by malaria-carrying mosquitos due to behavioral
206 differences such as working outside, not sleeping under a net, or traveling for work^{11,13,17,18}. In
207 our study, however, there were no statistically significant differences in malaria incidence or FOI
208 by sex, though there was a trend toward higher FOI in males. We also saw no evidence of
209 behavioral trends that would result in more infections in males; in fact, older women in our study
210 did most of the traveling outside the study area (an area of low transmission compared to
211 surrounding areas). We did not assess work habits as part of our study questionnaire, but the
212 fact that we observe similar patterns in prevalence by sex in all age categories makes this a less

213 likely explanation. Therefore, in this particular cohort, it appears that the observed male bias in
214 parasite prevalence is best explained by slower clearance of infection in males. We cannot rule
215 out that males were differentially exposed in the recent past (e.g., had a higher force of infection
216 when transmission was higher, which could have affected immunity), and we plan to genotype
217 samples from a prior cohort from 2011-2017 to test this hypothesis.

218 Very few studies have been conducted to explore immunological differences between
219 males and females in their response to the malaria parasite. RTS,S vaccination is associated
220 with higher all-cause mortality in girls compared to boys, and a trend toward higher risk of fatal
221 malaria has been noted in vaccinated girls compared to boys, suggesting possible sexual
222 dimorphism in immunological responses to malaria²³. The comprehensive Garki project found
223 that females had higher levels of antibodies against *P. falciparum* compared to men¹⁰. Hormonal
224 differences have been posited to play a role in these sex-based immunological differences to
225 malaria infection; studies in mice show that testosterone appears to downregulate the immune
226 response to malaria^{24,25}. If sex-based differences were purely hormonally mediated, one might
227 expect a stronger effect in adults than in school-aged children, which was not seen in this
228 cohort. This could be due to imperfect detectability, as adults have lower density infections than
229 school-aged children due to improved anti-parasite immunity^{2,3}. Post-menopausal women were
230 also included in the oldest age group, which could have blunted the effect of sex in that age
231 group if there is a hormonal basis for some of this effect. It is also possible that sex-based
232 differences are explained by a different mechanism, such as differences in innate immunity.
233 More studies are needed to elucidate the relationship between sex-based biological differences
234 between males and females and their impact on the development of effective antimalarial
235 immunity in humans.

236 Of the variables we evaluated in addition to sex, baseline infection status and parasite
237 density were most strongly associated with the rate of clearance of infection. Infections that
238 were already present at the beginning of the study and persisted past the left censoring date

239 may have been a non-random selection of well-established asymptomatic infections that were
240 present at baseline at a higher frequency than average because they had a fundamentally
241 different trajectory than newly established asymptomatic infections. Higher parasite densities
242 were also associated with slower clearance of infection in both adjusted models, but the effect
243 was most pronounced when the data were analyzed by infection event. This may be because
244 low-density infections that we were unable to successfully genotype were only included in the
245 infection event analysis, and these events tended to have short durations. The inclusion of
246 parasite density in our multivariate models did not meaningfully alter associations between sex
247 and duration of infection, providing evidence that the sex-based differences in duration were not
248 mediated primarily by differences in parasite density in our cohort.

249 A limitation of our study is the statistical model's assumption that all infections clear at
250 the same rate, which was necessary because we did not observe the beginning of most
251 infections. To rely less on this assumption, we adjusted for baseline infections, allowing them to
252 have a different rate of clearance than new infections; this did not change our primary finding of
253 a difference in rate of clearance by sex. We also acknowledge there may be other unmeasured
254 confounders, such as genetic hemoglobinopathies or sex-based differences in unreported
255 outside antimalarial use, that could affect our results. Another caveat is that our findings may
256 not be generalizable to areas with different transmission intensity given that our study was
257 conducted in a unique area with previously very high transmission intensity that has been
258 greatly reduced in recent years by repeated rounds of IRS.

259 Additionally, because it is difficult to genotype low density infections and because
260 parasite densities fluctuate over time, we allowed several "skips" in detection before declaring
261 an infection cleared or the same clone in an individual a new infection with the same clone. This
262 requires the assumption that re-infection with the same clone is relatively rare, which is
263 reasonable given the high genetic diversity and low force of infection seen in this setting; this

264 assumption has been made in other longitudinal genotyping studies^{26,27}. Our method may have
265 biased us toward longer durations of infection and fewer new infections overall, but this is
266 unlikely to have introduced any significant bias in the observed associations by sex. We
267 performed a sensitivity analysis to ensure that changing the number of skips allowed did not
268 significantly change the main finding regarding longer duration of infection in males and our
269 findings were consistent. Given decreasing parasite densities over time and a setting with low
270 force of infection and low EIR, assuming perfect recovery of clones is likely to artificially inflate
271 the force of infection in this cohort.

272 In summary, we estimated the clearance of asymptomatic *P. falciparum* infections by
273 genotyping longitudinal samples from a cohort in Nagongera, Uganda, using sensitive amplicon
274 deep-sequencing and found that females cleared their infections at a faster rate than males; this
275 finding remained consistent when adjusting for age, baseline infection status, and parasite
276 density. Furthermore, we found no conclusive evidence for a sex-based difference in exposure
277 to infection, either behaviorally or by FOI. Though there have long been observed differences in
278 malaria burden between the sexes, there is still little known about sex-based biological
279 differences that may mediate immunity to malaria. Unfortunately, much reported malaria data is
280 still sex-disaggregated. Our findings should encourage epidemiologists to better characterize
281 sexual dimorphism in malaria and motivate increased research into biological explanations for
282 sex-based differences in the host response to the malaria parasite.

283 Materials and Methods

284 Study setting and population-level malaria control interventions

285 This cohort study was carried out in Nagongera sub-county, Tororo district, eastern
286 Uganda, an area with historically high malaria transmission. However, 7 rounds of indoor
287 residual spraying (IRS) from 2014-2019 have resulted in a significant decline in the burden of

288 malaria²⁸. Pre-IRS, the daily human biting rate (HBR) was 34.3 and the annual entomological
289 inoculation rate (EIR) was 238; after 5 years of IRS, in 2019 the daily HBR was 2.07 and overall
290 annual EIR was 0.43 as reported by Nankabirwa et. al.²⁹

291

292 **Study design, enrollment, and follow-up**

293 All members of 80 randomly selected households with at least two children were
294 enrolled in October 2017 using a list generated by enumerating and mapping all households in
295 Nagongera sub-county²⁹. The cohort was dynamic such that residents joining the household
296 were enrolled and residents leaving the household were withdrawn. Data for this analysis was
297 collected from October 1st, 2017 through March 31st, 2019; participants were included if they
298 had at least 6 months of contiguous follow up. Participants were followed at a designated study
299 clinic open daily from 8 AM to 5 PM. Participants were encouraged to seek all medical care at
300 the study clinic and avoid the use of antimalarial medications outside of the study. Routine visits
301 were conducted every 28 days and included a standardized clinical evaluation, assessment of
302 overnight travel outside of Nagongera sub-county, and collection of blood by phlebotomy for
303 detection of malaria parasites by microscopy and molecular studies. Participants came in for
304 non-routine visits in the setting of illness. Blood smears were performed at enrollment, at all
305 routine visits and at non-routine visits if the participant presented with fever or history of fever in
306 the previous 24 hours. Participants with fever ($>38.0^{\circ}\text{C}$ tympanic) or history of fever in the
307 previous 24 hours had a thick blood smear read urgently. If the smear was positive, the patient
308 was diagnosed with malaria and treated with artemether-lumefantrine. Participants with
309 asymptomatic parasitemia as detected by qPCR or microscopy were not treated with
310 antimalarials, consistent with Uganda national guidelines. Study participants were visited at
311 home every 2 weeks to assess use of long-lasting insecticidal nets (LLINs) the previous night.

312

313 **Laboratory methods**

314 Thick blood smears were stained with 2% Giemsa for 30 minutes and evaluated for the
315 presence of asexual parasites and gametocytes. Parasite densities were calculated by counting
316 the number of asexual parasites per 200 leukocytes (or per 500, if the count was less than 10
317 parasites per 200 leukocytes), assuming a leukocyte count of 8,000/ μL . A thick blood smear was
318 considered negative if examination of 100 high power fields revealed no asexual parasites. For
319 quality control, all slides were read by a second microscopist, and a third reviewer settled any
320 discrepant readings. In our experienced microscopists' hands, the lower limit of detection is
321 approximately 20-50 parasites/ μL .

322 For qPCR and genotyping, we collected 200 μL of blood at enrollment, at each routine
323 visit, and at the time of malaria diagnosis. DNA was extracted using the PureLink Genomic DNA
324 Mini Kit (Invitrogen) and parasitemia was quantified using an ultrasensitive varATS qPCR assay
325 with a lower limit of detection of 0.05 parasites/ μL ³⁰. Samples with a parasite density ≥ 0.1
326 parasites/ μL blood were genotyped via amplicon deep-sequencing. All samples positive for
327 asexual parasites by microscopy but negative for *P. falciparum* by qPCR were tested for the
328 presence of non-falciparum species using nested PCR.³¹

329

330 *Sequencing library preparation*

331 Hemi-nested PCR was used to amplify a 236 base-pair segment of apical membrane
332 antigen 1 (AMA-1) using a published protocol³², with modifications (**Supplemental File 1a**).
333 Samples were amplified in duplicate, indexed, pooled, and purified by bead cleaning.
334 Sequencing was performed on an Illumina MiSeq platform (250bp paired-end).

335

336 **Bioinformatics methods**

337 Data extraction, processing, and haplotype clustering were performed using SeekDeep³³,
338 followed by additional filtering³⁴. **Supplemental File 1b** shows the full bioinformatics workflow.

339

340 **Data analysis**

341 A clone was defined as a genetically identical group of parasites, e.g., with identical
342 haplotypes. Because polyclonal infections can occur due to co-infection (one mosquito bite
343 transmitting multiple clones) or superinfection (multiple bites), we analyzed the infection data
344 both by clone and by infection event. For analysis by clone, each unique clone was counted as
345 an infection and each clone's disappearance as a clearance event. For analysis by infection
346 event, any new clones seen within 3 visits of the date of the first newly detected clone(s) were
347 grouped together and considered one new "infection event." Clearance of infection for these
348 events required that all clones in the group be absent. A baseline infection was defined as a
349 clone or infection event (group of clones) detected in the first 60 days of observation. New
350 infections were defined as a new clone or infection event (group of clones) detected in an
351 individual after day 60.

352 Imperfect detection of *P. falciparum* clones is known to be a limitation of all PCR-based
353 genotyping methods; both biological factors, such as deep organ sequestration of clones in the
354 lifecycle of the parasite, and methodological factors, such as difficulty amplifying minority clones
355 (especially at lower parasite densities), results in imperfect detectability of all clones present in a
356 single blood sample drawn on a single day.^{26,35–38} Though amplicon deep sequencing is less
357 likely than other methods to miss minority clones³⁹, detectability was a particular concern in our
358 study, in which the majority of infections were submicroscopic and parasite densities declined
359 over time [Supplemental File 1c]. To account for the fact that a clone might be missed in a
360 single sample due to fluctuations in parasite density and/or methodological limitations, we
361 allowed 3 "skips" in detection and classified an infection as cleared only if it was not identified in
362 4 contiguous samples from routine visits. If the infection (as determined by clone or by infection
363 event) was absent for 4 routine samples in a row, the last date of detection would be the end
364 date of that infection. Therefore, for a clone that had previously infected an individual to be

365 classified as a new infection, it had to have been absent from that individual for at least 4 routine
366 visits. Additional details are found in **Supplemental File 1d**. This decision was supported by the
367 fact that the diversity of the genotyped AMA-1 amplicon was quite high (expected
368 heterozygosity = 0.949), resulting in a low probability (5.1%) for infection with the same clone by
369 chance.


370 Data analysis was conducted in R⁴⁰ and Python⁴¹. Microscopic parasite prevalence was
371 defined by the number of smear-positive routine visits over all routine visits. Parasite prevalence
372 by qPCR was defined as the number of qPCR-positive visits over all routine visits. Prevalence
373 ratios were computed using Poisson regression with generalized estimating equations to adjust
374 for repeated measures. Comparison of parasite density by sex was made using linear
375 regression with generalized estimating equations to adjust for repeated measures. Force of
376 infection (FOI) was defined as the number of new infections, including malaria episodes, divided
377 by person time. Poisson regression with generalized estimating equations to account for
378 repeated measures was used to estimate malaria incidence, FOI, and to calculate incident rate
379 ratios (IRR) for malaria and FOI. Hazards for clearance of untreated, asymptomatic infections
380 were estimated using time-to-event models (shared frailty models fit using R package
381 “frailtypack,” version 2.12.2)^{42,43}. Infections were censored if they were only observed in the first
382 three months or the last three months (before January 01, 2018 and after January 01, 2019)
383 because they were not observed for long enough to determine whether clearance occurred. If
384 an infection was observed for only one timepoint, it was assigned a duration of 14 days. These
385 models assumed a constant hazard of clearance and included random effects to account for
386 repeated measures in individuals. Parasite density was included in the model as a time-varying
387 covariate. Duration of infection in days was calculated as 1/adjusted hazard.

388 **Data Accessibility**

389 Data from the cohort study is available through an open-access clinical epidemiology
390 database resource, ClinEpiDB at https://clinepidb.org/ce/app/record/dataset/DS_51b40fe2e2.
391 Genotyping data and code used to generate tables and figures is available on GitHub⁴⁴.
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414

415 **Figure Legends**

416 **Figure 1. Study design.**



417

418

419

420

421

422

423


424

425

426

427 **Figure 2. Estimates of duration of infection from sex- and age-adjusted model**

428



429

430 Estimated duration of infection in days, calculated by adjusting the point estimate of the baseline
431 hazard by the coefficients of the sex- and age-adjusted model. Error bars represent standard
432 errors of duration obtained from variance in the model coefficients. Point estimates of duration
433 are labeled (*).

434

435

436

437

438

439 **Supplemental File Legends**

440
441 **Supplemental File 1a. AMA-1 hemi-nested PCR protocol for amplicon deep-sequencing**
442 **Supplemental File 1b: Bioinformatics workflow**
443 **Supplemental File 1c. Declining qPCR density over time in the cohort.**
444 **Supplemental File 1d. Detailed explanation of skip rule criteria**
445 **Supplemental File 1e. Haplotype sequences and frequencies**
446 **Supplemental File 1f. Sensitivity analysis of molecular force of infection: Table 2**
447 **replicated using 2 skips or 1 skip**
448 **Supplemental File 1g. Sensitivity analysis of duration of infection: Table 3 replicated**
449 **using 2 skips or 1 skip**

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466 **Table 1. Behavioral risk factors for malaria infection and measures of malaria burden in study population, stratified by age and sex**
 467

Metric	Age and gender categories							
	All		< 5 years old		5-15 years old		16 years and older	
	Male	Female	Male	Female	Male	Female	Male	Female
Number of participants, n	233	244	73	84	101	71	59	89
Median days of follow-up per participant	530.0	530.0	525.0	524.5	530.0	531.0	530.0	530.0
Slept under LLIN the previous night	53.6%	56.3%	54.1%	56.3%	47.9%	47.8%	63.7%	64.3%
Person-years of follow up	324.2	345.4	87.3	96.7	152.6	118.5	84.22	130.1
Number of overnight trips	44	107	21	19	9	10	14	78
Incidence of overnight trips*, (95% CI)	0.14 (0.09-0.20)	0.31 (0.20-0.49)	0.24 (0.14-0.42)	0.20 (0.09-0.42)	0.06 (0.03-0.13)	0.08 (0.03-0.24)	0.17 (0.09-0.31)	0.60 (0.30-1.18)
Episodes of malaria**, (incidence*)	11	13	5	2	5	9	1	2
Incidence of malaria*, (95% CI)	0.03 (0.02-0.06)	0.04 (0.02-0.09)	0.06 (0.02-0.16)	0.02 (0.00-0.11)	0.03 (0.01-0.08)	0.08 (0.03-0.23)	0.01 (0.00-0.08)	0.02 (0.00-0.17)
Number of routine visits, n	4,316	4,583	1164	1293	2034	1568	1118	1722
Prevalence of microscopic parasitemia***	2.9%	1.4%	1.8%	1.1%	4.4%	2.7%	1.3%	0.5%
Prevalence of parasitemia by qPCR	14.4%	9.2%	5.8%	3.7%	17.0%	15.3%	18.5%	7.7%
Geometric mean parasite density****	3.41	3.06	4.86	13.06	6.31	4.20	1.09	1.02
Median complexity of infection, (IQR)	3 (1-7)	2 (1-2)	1 (1-2.5)	2 (1-2.3)	4 (2-9)	2 (1-2)	1 (1-2)	1 (1-2)

468 *per person-year

469 **Malaria includes 1 episode (female, < 5 years old), due to non-falciparum species (*P. malariae*)

470 ***Parasitemia by light microscopy includes 1 episode (female, 5-15 years old) due to non-falciparum species (*P. ovale*)

471 ****Geometric mean parasite density in parasites/uL of all qPCR-positive routine visits

472

Table 2. Molecular force of infection (FOI) by clone and by infection event, stratified by age and sex

473

	Molecular force of infection (FOI)	Sex	Age category			
			All	< 5 years	5-15 years	16 years or older
By clone, ppy* (95% CI)	All		0.18 (0.13-0.24)	0.14 (0.07-0.28)	0.19 (0.08-0.43)	0.20 (0.08-0.46)
	Male		0.19 (0.12-0.30)	0.16 (0.07-0.39)	0.19 (0.10-0.37)	0.22 (0.09-0.54)
	Female		0.17 (0.09-0.31)	0.12 (0.03-0.49)	0.19 (0.08-0.45)	0.18 (0.06-0.54)
By event, ppy* (95% CI)	All		0.14 (0.11-0.18)	0.09 (0.06-0.16)	0.16 (0.09-0.30)	0.16 (0.08-0.32)
	Male		0.16 (0.11-0.22)	0.13 (0.07-0.27)	0.18 (0.11-0.28)	0.15 (0.07-0.29)
	Female		0.13 (0.08-0.21)	0.06 (0.02-0.18)	0.14 (0.07-0.27)	0.17 (0.07-0.41)

474

*per person-year

475 **Table 3. Hazard ratios for rates of clearance of infection, by clone and by infection event**

476

Predictors	Categories	Hazard ratio by clone (95% CI)		Hazard ratio by infection event (95% CI)	
		Unadjusted	Adjusted	Unadjusted	Adjusted
Sex	Male	ref	ref	ref	ref
	Female	1.92 (1.19–3.11)	1.82 (1.20 – 2.75)	2.30 (1.20 – 4.42)	2.07 (1.24 – 3.47)
Age	16 years or greater	ref	ref	ref	ref
	5-15 years	0.66 (0.39 – 1.10)	0.81 (0.49 – 1.36)	0.82 (0.39 – 1.74)	1.27 (0.72 – 2.25)
Complexity of infection (COI)	Polyclonal (COI > 1)	ref	--	ref	--
	Monoclonal (COI = 1)	1.63 (1.03 – 2.57)	--	0.95 (0.38 – 2.34)	--
Infection status	Present at baseline	ref	ref	ref	ref
	New infection	1.94 (1.22 – 3.07)	1.75 (1.05 – 2.94)	4.66 (2.58 – 8.42)	4.32 (2.59 – 7.20)
Parasite density *		0.85 (0.69 – 1.06)	0.81 (0.65 – 1.00)	0.41 (0.32 – 0.51)	0.44 (0.35 – 0.54)

477 *Increasing parasite density (log10) in parasites/microliter, as measured by qPCR

478

479

480

481

482

483

484

485 REFERENCES

486

- 487 1. World malaria report 2019 [Internet]. [cited 2020 Aug 5]. Available from:
488 <https://www.who.int/publications-detail-redirect/9789241565721>
- 489 2. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability,
490 transmissibility and public health relevance. *Nat Rev Microbiol.* 2014;12(12):833–840.
491 PMID: 25329408
- 492 3. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. Factors determining
493 the occurrence of submicroscopic malaria infections and their relevance for control.
494 *Nature Communications.* 2012 Dec 4;3(1):1–9.
- 495 4. Tadesse FG, Slater HC, Chali W, Teelen K, Lanke K, Belachew M, Menberu T, Shumie G,
496 Shitaye G, Okell LC, Graumans W, van Gemert G-J, Kedir S, Tesfaye A, Belachew F, Abebe
497 W, Mamo H, Sauerwein R, Balcha T, Aseffa A, Yewhalaw D, Gadisa E, Drakeley C, Bousema
498 T. The Relative Contribution of Symptomatic and Asymptomatic Plasmodium vivax and
499 Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic Setting in
500 Ethiopia. *Clin Infect Dis.* 2018 01;66(12):1883–1891. PMID: 29304258
- 501 5. Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, Gonçalves BP, Björkman A,
502 Ouedraogo AL, Morris U, Msellem M, Koepfli C, Mueller I, Tadesse F, Gadisa E, Das S,
503 Domingo G, Kapulu M, Midega J, Owusu-Agyei S, Nabet C, Piarroux R, Doumbo O, Doumbo
504 SN, Koram K, Lucchi N, Udhayakumar V, Mosha J, Tiono A, Chandramohan D, Gosling R,
505 Mwingira F, Sauerwein R, Riley EM, White NJ, Nosten F, Imwong M, Bousema T, Drakeley
506 C, Okell LC. The temporal dynamics and infectiousness of subpatent Plasmodium
507 falciparum infections in relation to parasite density. *Nature Communications.* 2019 Mar
508 29;10(1):1433.
- 509 6. Zuk M, McKean KA. Sex differences in parasite infections: Patterns and processes.
510 *International Journal for Parasitology.* 1996 Oct 1;26(10):1009–1024.
- 511 7. Klein SL. Hormonal and immunological mechanisms mediating sex differences in parasite
512 infection. *Parasite Immunology.* 2004;26(6–7):247–264.
- 513 8. Roberts CW, Walker W, Alexander J. Sex-Associated Hormones and Immunity to Protozoan
514 Parasites. *Clin Microbiol Rev.* 2001 Jul 1;14(3):476–488.
- 515 9. Desai M, Kuile FO ter, Nosten F, McGready R, Asamoah K, Brabin B, Newman RD.
516 Epidemiology and burden of malaria in pregnancy. *The Lancet Infectious Diseases.* 2007
517 Feb 1;7(2):93–104. PMID: 17251080
- 518 10. Molineaux L, Gramiccia G, Organization WH. The Garki project: research on the
519 epidemiology and control of malaria in the Sudan savanna of West Africa [Internet]. World

- 520 Health Organization; 1980 [cited 2020 Feb 18]. Available from:
521 <https://apps.who.int/iris/handle/10665/40316>
- 522 11. Pathak S, Rege M, Gogtay NJ, Aigal U, Sharma SK, Valecha N, Bhanot G, Kshirsagar NA,
523 Sharma S. Age-Dependent Sex Bias in Clinical Malarial Disease in Hypoendemic Regions.
524 PLoS One [Internet]. 2012 Apr 25 [cited 2020 Feb 18];7(4). Available from:
525 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338423/> PMCID: PMC3338423
- 526 12. Landgraf B, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Parasite density of
527 Plasmodium falciparum malaria in Ghanaian schoolchildren: evidence for influence of sex
528 hormones? Transactions of the Royal Society of Tropical Medicine and Hygiene. 1994
529 Jan;88(1):73–74.
- 530 13. Camargo LMA, Colletto GMDD, Ferreira MU, Gurgel SDM, Escobar AL, Marques A, Krieger
531 H, Camargo EP, Silva LHPD. Hypoendemic Malaria in Rondonia (Brazil, Western Amazon
532 Region): Seasonal Variation and Risk Groups in an Urban Locality. The American Journal of
533 Tropical Medicine and Hygiene. 1996 Jul 1;55(1):32–38.
- 534 14. Abdalla SI, Malik EM, Ali KM. The burden of malaria in Sudan: incidence, mortality and
535 disability – adjusted life – years. Malar J. 2007 Jul 28;6:97. PMCID: PMC1995207
- 536 15. Houngbedji CA, N'Dri PB, Hürlimann E, Yapi RB, Silué KD, Soro G, Koudou BG, Acka CA, Assi
537 S-B, Vounatsou P, N'Goran EK, Fantodji A, Utzinger J, Raso G. Disparities of Plasmodium
538 falciparum infection, malaria-related morbidity and access to malaria prevention and
539 treatment among school-aged children: a national cross-sectional survey in Côte d'Ivoire.
540 Malar J [Internet]. 2015 Jan 5 [cited 2020 Aug 5];14. Available from:
541 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326184/> PMCID: PMC4326184
- 542 16. Mulu A, Legesse M, Erko B, Belyhun Y, Nugussie D, Shimelis T, Kassu A, Elias D, Moges B.
543 Epidemiological and clinical correlates of malaria-helminth co-infections in southern
544 Ethiopia. Malar J. 2013 Jul 3;12:227. PMCID: PMC3706225
- 545 17. Moon JJ, Cho S-Y. Incidence patterns of vivax malaria in civilians residing in a high-risk
546 county of Kyonggi-do (Province), Republic of Korea. Korean J Parasitol. 2001
547 Dec;39(4):293–299. PMCID: PMC2721214
- 548 18. Finda MF, Moshi IR, Monroe A, Limwagu AJ, Nyoni AP, Swai JK, Ngowo HS, Minja EG, Toe
549 LP, Kaindoa EW, Coetzee M, Manderson L, Okumu FO. Linking human behaviours and
550 malaria vector biting risk in south-eastern Tanzania. PLoS One [Internet]. 2019 Jun 3 [cited
551 2020 Apr 8];14(6). Available from:
552 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546273/> PMCID: PMC6546273
- 553 19. Nhamoyebonde S, Leslie A. Biological Differences Between the Sexes and Susceptibility to
554 Tuberculosis. J Infect Dis. 2014 Jul 15;209(suppl_3):S100–S106.

- 555 20. Bernin H, Lotter H. Sex Bias in the Outcome of Human Tropical Infectious Diseases:
556 Influence of Steroid Hormones. *J Infect Dis.* 2014 Jul 15;209(suppl_3):S107–S113.
- 557 21. Fischer J, Jung N, Robinson N, Lehmann C. Sex differences in immune responses to
558 infectious diseases. *Infection.* 2015 Aug 1;43(4):399–403.
- 559 22. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. *Nat*
560 *Rev Immunol.* 2008 Sep;8(9):737–744.
- 561 23. Klein SL, Shann F, Moss WJ, Benn CS, Aaby P. RTS,S Malaria Vaccine and Increased
562 Mortality in Girls. *mBio* [Internet]. 2016 Apr 26 [cited 2020 Feb 18];7(2). Available from:
563 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850267/> PMCID: PMC4850267
- 564 24. Delić D, Ellinger-Ziegelbauer H, Vohr HW, Dkhil M, Al-Quraishi S, Wunderlich F.
565 Testosterone response of hepatic gene expression in female mice having acquired
566 testosterone-unresponsive immunity to Plasmodium chabaudi malaria. *Steroids.* 2011
567 Oct;76(10–11):1204–1212. PMID: 21669218
- 568 25. Wunderlich, F, Marinovski P, Peter W, Benten M, Schmitt-Wrede, H-P, Mossman H.
569 Testosterone and Other Gonadal Factor(s) Restrict the Efficacy of Genes Controlling
570 Resistance to Plasmodium Chabaudi Malaria [Internet]. *Parasite immunology.* 1991.
571 *Parasite Immunology,* 13: 357-367. doi:10.1111/j.1365-3024.1991.tb00289.x
- 572 26. Felger I, Maire M, Bretscher MT, Falk N, Tiaden A, Sama W, Beck H-P, Owusu-Agyei S,
573 Smith TA. The Dynamics of Natural Plasmodium falciparum Infections. *PLOS ONE.* 2012
574 Sep 18;7(9):e45542.
- 575 27. Smith T, Felger I, Fraser-Hurt N, Beck H-P. 10. Effect of insecticide-treated bed nets on the
576 dynamics of multiple Plasmodium falciparum infections. *Transactions of the Royal Society*
577 *of Tropical Medicine and Hygiene.* 1999 Feb 1;93:53–57.
- 578 28. Nankabirwa JL, Briggs J, Rek J, Arinaitwe E, Nayebare P, Katrak S, Staedke SG, Rosenthal PJ,
579 Rodriguez-Barraquer I, Kamya MR, Dorsey G, Greenhouse B. Persistent Parasitemia
580 Despite Dramatic Reduction in Malaria Incidence After 3 Rounds of Indoor Residual
581 Spraying in Tororo, Uganda. *J Infect Dis.* 2019 Mar 15;219(7):1104–1111. PMCID:
582 PMC6420168
- 583 29. Nankabirwa JL, Arinaitwe E, Rek J, Kilama M, Kizza T, Staedke SG, Rosenthal PJ, Rodriguez-
584 Barraquer I, Briggs J, Greenhouse B, Bousema T, Drakeley C, Roos DS, Tomko SS, Smith DL,
585 Kamya MR, Dorsey G. Malaria Transmission, Infection, and Disease following Sustained
586 Indoor Residual Spraying of Insecticide in Tororo, Uganda. *The American Journal of*
587 *Tropical Medicine and Hygiene;* 2020 Jul 20;tpmd200250.
- 588 30. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
589 detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets.
590 *PLoS Med.* 2015 Mar;12(3):e1001788. PMCID: PMC4348198

- 591 31. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown
592 KN. High sensitivity of detection of human malaria parasites by the use of nested
593 polymerase chain reaction. *Mol Biochem Parasitol.* 1993 Oct;61(2):315–320. PMID:
594 8264734
- 595 32. Miller RH, Hathaway NJ, Kharabora O, Mwandagalirwa K, Tshefu A, Meshnick SR, Taylor
596 SM, Juliano JJ, Stewart VA, Bailey JA. A deep sequencing approach to estimate Plasmodium
597 falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity.
598 *Malar J.* 2017 Dec 16;16(1):490. PMCID: PMC5732508
- 599 33. Hathaway NJ, Parobek CM, Juliano JJ, Bailey JA. SeekDeep: single-base resolution de novo
600 clustering for amplicon deep sequencing. *Nucleic Acids Res.* 2018 Feb 28;46(4):e21–e21.
- 601 34. Lerch A, Koepfli C, Hofmann NE, Kattenberg JH, Rosanas-Urgell A, Betuela I, Mueller I,
602 Felger I. Longitudinal tracking and quantification of individual Plasmodium falciparum
603 clones in complex infections. *Sci Rep [Internet].* 2019 Mar 4 [cited 2020 Feb 18];9.
604 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399284/> PMCID:
605 PMC6399284
- 606 35. Koepfli C, Mueller I. Malaria Epidemiology at the Clone Level. *Trends Parasitol.* 2017
607 Dec;33(12):974–985. PMCID: PMC5777529
- 608 36. Nguyen T-N, von Seidlein L, Nguyen T-V, Truong P-N, Hung SD, Pham H-T, Nguyen T-U, Le
609 TD, Dao VH, Mukaka M, Day NP, White NJ, Dondorp AM, Thwaites GE, Hien TT. The
610 persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium
611 vivax infections over time in Vietnam: an open cohort study. *Lancet Infect Dis.* 2018
612 May;18(5):565–572. PMCID: PMC5910058
- 613 37. Koepfli C, Schoepflin S, Bretscher M, Lin E, Kiniboro B, Zimmerman PA, Siba P, Smith TA,
614 Mueller I, Felger I. How much remains undetected? Probability of molecular detection of
615 human Plasmodia in the field. *PLoS ONE.* 2011 Apr 28;6(4):e19010. PMCID: PMC3084249
- 616 38. Ross A, Koepfli C, Li X, Schoepflin S, Siba P, Mueller I, Felger I, Smith T. Estimating the
617 numbers of malaria infections in blood samples using high-resolution genotyping data.
618 *PLoS ONE.* 2012;7(8):e42496. PMCID: PMC3430681
- 619 39. Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, Betuela I, O'Connor L,
620 Mueller I, Felger I. Development of amplicon deep sequencing markers and data analysis
621 pipeline for genotyping multi-clonal malaria infections. *BMC Genomics.* 2017 Nov
622 13;18(1):864.
- 623 40. R Core Team. R: A language and environment for statistical computing. [Internet]. R
624 Foundation for Statistical Computing, Vienna, Austria.; 2019. Available from: URL
625 <https://www.R-project.org/>.

- 626 41. Python Language Reference, version 3.7.4. [Internet]. Python Software Foundation.;
627 Available from: Available at <http://www.python.org>
- 628 42. Rondeau V, Gonzalez JR. frailtypack: A computer program for the analysis of correlated
629 failure time data using penalized likelihood estimation. Computer Methods and Programs
630 in Biomedicine. 2005 Nov 1;80(2):154–164.
- 631 43. Rondeau V, Marzroui Y, Gonzalez JR. frailtypack: An R Package for the Analysis of
632 Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or
633 Parametrical Estimation. Journal of Statistical Software. 2012 Apr 17;47(1):1–28.
- 634 44. Briggs J. 2020. Sex_based_differences. Github.
635 https://github.com/EPPIcenter/sex_based_differences.git. cf6c325.

636